Retinoic acid-induced protein 3: Identification and characterisation of a novel prognostic colon cancer biomarker

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 531-539

  Zougman, Alexandre ^a   Hutchins, Gordon G ^b   Cairns, David A ^a   Verghese, Eldo ^b   Perry, Sarah L ^c   Jayne, David G ^c   Selby, Peter J ^a   Banks, Rosamonde E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Biomarkers; Colon cancer; GPRC5a; Label free proteomics; RAI3

Indexed keywords

MEMBRANE PROTEIN; RETINOIC ACID INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COLON CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MICE; MIDDLE AGED; PROGNOSIS; PROTEOMICS; RECEPTORS, G-PROTEIN-COUPLED; TUMOR MARKERS, BIOLOGICAL;

EID: 84872106030     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.031     Document Type: Article

References (29)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. R. Labianca, and B. Merelli Screening and diagnosis for colorectal cancer: present and future Tumor 96 6 2010 889 901
3. E.J. Morris, N.J. Maughan, D. Forman, and P. Quirke Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology Gut 56 10 2007 1419 1425
4. J.L. Marshall, D.G. Haller, and A. de Gramont Adjuvant therapy for stage II and III colon cancer: consensus report of the international society of gastrointestinal oncology Gastrointest Cancer Res 1 4 2007 146 154
5. P. Quirke, and E. Morris Reporting colorectal cancer Histopathology 50 1 2007 103 112
6. S. Tejpar, M. Bertagnolli, and F. Bosman Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery Oncologist 15 4 2010 390 404
7. C.R. Jimenez, J.C. Knol, G.A. Meijer, and R.J. Fijneman Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers J Proteomics 73 10 2010 1873 1895
8. J.R. Wisniewski, P. Ostasiewicz, and M. Mann High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers J Proteome Res 10 7 2011 3040 3049
9. J.R. Wisniewski, A. Zougman, N. Nagaraj, and M. Mann Universal sample preparation method for proteome analysis Nat Methods 6 5 2009 359 362
10. J.R. Wisniewski, A. Zougman, and M. Mann Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome J Proteome Res 8 12 2009 5674 5678
11. J. Cox, I. Matic, and M. Hilger A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics Nat Protoc 4 5 2009 698 705
12. H. Jorissen, N. Bektas, and E. Dahl Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer BMC Cancer 9 2009 200
13. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumor MARKer prognostic studies (REMARK) Nat Clin Pract Oncol 2 8 2005 416 422
14. D.A. Schoenfeld Sample-size formula for the proportional-hazards regression model Biometrics 39 2 1983 499 503
15. P.M. Grambsch, and T.M. Therneau Proportional hazards tests and diagnostics based on weighted residuals Biometrika 81 3 1994 515 526
16. M.A. Hediger, M.J. Coady, T.S. Ikeda, and E.M. Wright Expression cloning and cDNA sequencing of the Na+/glucose co-transporter Nature 330 6146 1987 379 381
17. M. Pineda, E. Fernandez, and D. Torrents Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an l-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids J Biol Chem 274 28 1999 19738 19744
18. H. Wei, S. Wang, and D. Zhang Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice Clin Cancer Res 15 14 2009 4612 4621
19. P. Zhang, T. Ozdemir, C.Y. Chung, G.P. Robertson, and C. Dong Sequential binding of alphaVbeta3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils J Immunol 186 1 2011 242 254
20. A. Zarbock, R.K. Polanowska-Grabowska, and K. Ley Platelet-neutrophil- interactions: linking hemostasis and inflammation Blood Rev 21 2 2007 99 111
21. S. Seaman, J. Stevens, and M.Y. Yang Genes that distinguish physiological and pathological angiogenesis Cancer Cell 11 6 2007 539 554
22. M.B. Resnick, T. Konkin, J. Routhier, E. Sabo, and V.E. Pricolo Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study Mod Pathol 18 4 2005 511 518
23. S.R. Kumar, J.S. Scehnet, and E.J. Ley Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression Cancer Res 69 9 2009 3736 3745
24. Y. Cheng, and R. Lotan Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor J Biol Chem 273 52 1998 35008 35015
25. X.H. Tang, and L.J. Gudas Retinoids, retinoic acid receptors, and cancer Annu Rev Pathol 6 2011 345 364
26. Q. Tao, J. Fujimoto, and T. Men Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene J Natl Cancer Inst 99 22 2007 1668 1682
27. H. Kadara, J. Fujimoto, and T. Men A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas Neoplasia 12 6 2010 499 505
28. T. Nagahata, T. Sato, and A. Tomura Identification of RAI3 as a therapeutic target for breast cancer Endocr Relat Cancer 12 1 2005 65 73
29. R.G. Gray, P. Quirke, and K. Handley Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer J Clin Oncol 29 35 2011 4611 4619